Gemini Therapeutics (NASDAQ: GMTX)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Gemini Therapeutics (NASDAQ: GMTX) through any online brokerage.
The latest price target for Gemini Therapeutics (NASDAQ: GMTX) was reported by HC Wainwright & Co. on Friday, March 11, 2022. The analyst firm set a price target for 2.00 expecting GMTX to rise to within 12 months (a possible 28.21% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Gemini Therapeutics (NASDAQ: GMTX) is $1.56 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Gemini Therapeutics.
Gemini Therapeutics’s Q2 earnings are confirmed for Friday, August 19, 2022.
There is no upcoming split for Gemini Therapeutics.
Gemini Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.